Blue Cross Blue Shield covers medically necessary dermatology services, including skin cancer screenings, biopsies, lesion destruction, and treatment of chronic conditions such as eczema, psoriasis, and acne, and excludes cosmetic procedures across nearly all plans. For a provider, the harder question is not whether a service is covered but how to get it paid, because coverage rules, prior authorization triggers, delegated review vendors, and timely filing windows differ across the more than 30 independent Blue plans.
This guide maps those rules so your dermatology claims clear on the first submission and your denials get overturned when they do not.
BCBS covers dermatology when the service is medically necessary and documented to the payer’s policy. Coverage, prior authorization, and appeal rules are set by each local Blue plan, not by a single national insurer, so the same procedure can be approved by one Blue affiliate and denied by another. To get paid on the first pass: verify eligibility and benefits before the date of service, confirm whether the service or drug needs prior authorization, code to the supporting diagnosis with the correct modifier, and submit within the affiliate’s filing window. When a claim is denied, read the CARC code first, request a peer-to-peer before filing a written appeal where a clinical reviewer is involved, and cite the plan’s own medical policy in the appeal.
What BCBS Considers Medically Necessary?
BCBS plans draw a sharp line between medical dermatology and cosmetic procedures. Medical dermatology addresses health conditions and is generally covered.
BCBS of Western New York defines medically necessary services as those for which there is a functional impairment and the procedure is expected to improve it.
Medical dermatology services that BCBS covers include skin cancer screenings and biopsies; treatments for chronic conditions such as eczema, psoriasis, and rosacea; acne management; medically necessary mole removal; and treatment of actinic keratosis and other premalignant lesions.
When a provider documents that a lesion is symptomatic or has malignant potential, BCBS treats the service as medically necessary.
For example, destruction of actinic keratosis (L57.0) is covered because it is a pre-malignant condition. Inflamed seborrheic keratoses (L82.0) are generally covered because the inflammation establishes medical necessity.
What BCBS Considers Cosmetic?
Cosmetic procedures are defined as those intended to change physical appearance that fall within the range of normal human anatomic variation.
These services are excluded from coverage under virtually all BCBS plans.
Services typically denied as cosmetic include chemical peels for photoaged skin or wrinkles; dermabrasion for acne scars; laser hair removal for hirsutism or other indications; laser skin resurfacing for facial wrinkles; microneedling for acne scars or blemishes; and tattoo removal.
BCBS of North Carolina’s reimbursement policy specifically states that services considered cosmetic or not medically necessary are non-covered, and any associated services related to a denied procedure are also denied.
This means that if the primary service is denied for cosmetic reasons, you cannot bill for the facility or ancillary services either.
Where the Line Gets Blurred?
Some procedures can be either cosmetic or reconstructive depending on the clinical circumstances.
For example, treatment of cutaneous hemangiomas, port wine birthmarks, and other vascular lesions is considered reconstructive when intended to address a deviation from normal related to a congenital disability.
The same treatment would be considered cosmetic if performed solely to restore appearance and not to address functional impairment.
Treatment of rosacea is considered medically necessary when the rosacea is severe, refractory to standard medical therapy, and preoperative photos document clinical skin changes requiring treatment.
Without those documentation elements, the same treatment may be denied as cosmetic.
The documentation must clearly establish medical necessity.
If a procedure could be perceived as cosmetic, include specific clinical findings that justify the medical indication.
Avoid general terms like “patient requested removal” or “patient bothered by appearance.”
Plan Types and Their Coverage Rules
HMO Plans
HMO plans generally require a referral from the patient’s Primary Care Provider before the patient can see a dermatologist. If the patient shows up without a referral, the claim will be denied regardless of medical necessity.
Verify referral status before the appointment. Do not assume the patient knows whether they need a referral.
Call the PCP’s office if necessary. A denied claim due to a missing referral is completely preventable.
PPO Plans
PPO plans typically allow patients to see a dermatologist directly without a referral. However, patients pay less when they see in-network providers.
Out-of-network care may be covered at a lower percentage or not at all.
The Federal Employee Program (FEP)
FEP has specific provisions for dermatology care.
The 2026 brochure explicitly lists “telehealth professional services for dermatology care” as a covered benefit under both the Standard and Basic Options.
This confirms that BCBS recognizes teledermatology as a legitimate care delivery model for its federal employees.
Medicare Advantage Plans
BCBS Medicare Advantage plans cover dermatology services in accordance with Medicare guidelines.
This means coverage follows Medicare’s rules for medical necessity, but the specific cost-sharing and prior authorization requirements vary by plan.
How the BCBS federation changes your billing
Blue Cross Blue Shield operates as a federation of more than 30 independent, locally licensed companies, which means a single national coverage answer for dermatology does not exist. Anthem (Elevance), Health Care Service Corporation (which operates the Blue plans in Illinois, Texas, New Mexico, Oklahoma, and Montana), Florida Blue, Highmark, Blue Cross NC, Premera, CareFirst, BCBS of Massachusetts, and BCBS of Michigan each maintain their own medical policies, prior authorization lists, claim portals, fax numbers, and appeal forms.
Two structural rules follow from the federation, and both drive dermatology denials.
BlueCard (out-of-area Blue members)
When you treat a patient whose Blue plan is based in another state, you submit the claim to your local Blue plan, which routes it to the member’s home plan through the BlueCard program. Prior authorization and medical policy follow the member’s home plan, not yours. Confirm the home plan’s rules before the service, not after the denial.
Fully insured versus self-funded (ASO / ERISA) plans
Many BCBS cards are self-funded employer plans that BCBS only administers; the employer sets the benefit and funds the claim. Self-funded plans are governed by ERISA and are not bound by state coverage mandates, so a dermatology service mandated as covered in your state may still be excluded on a self-funded card. The card alone does not tell you. Verify funding type during eligibility so you bill the correct rule set.
How to verify BCBS dermatology coverage before the visit
Eligibility verification confirms that a patient’s BCBS plan is active and that the specific dermatology service is a covered benefit before the date of service. Active coverage and a covered benefit are not the same thing, and most front-end dermatology denials trace to verifying the first and assuming the second.
Run verification through the affiliate’s provider portal, which for many Blue plans is Availity Essentials, or through a real-time 270/271 eligibility transaction in your practice management system For each dermatology encounter, confirm: plan funding type (fully insured or self-funded), referral requirement (HMO plans typically require a PCP referral), prior authorization requirement at the procedure-code or drug level, the patient’s remaining deductible and coinsurance, and in-network status for the rendering provider and the facility.
Capture the patient’s expected financial responsibility at this stage so the front desk can collect or set an estimate, and so a covered-but-cost-shared service is not mistaken for a denial later. A disciplined pre-billing check is the cheapest denial you will ever prevent, and it is the first thing UControl standardizes when it takes over a dermatology practice’s revenue cycle.
Telehealth Dermatology Coverage
The MDLIVE Partnership
A significant development for 2026 is the expansion of teledermatology services through MDLIVE.
BCBS announced that, starting January 1, 2026, they would expand their partnership with MDLIVE to include teledermatology services.
This brings even more care options to members.
The 2026 FEP brochure confirms that “telehealth professional services for dermatology care” are covered under the standard benefit.
This is a permanent feature of the benefit, not a temporary COVID-era exception.
What Teledermatology Covers
MDLIVE’s teledermatology service provides diagnosis, treatment, and prescriptions for over 3,000 skin, hair, and nail conditions.
The service includes photo uploads and asynchronous review, allowing dermatologists to evaluate conditions without real-time video.
Offering telehealth dermatology services aligns with current BCBS coverage trends and can capture patients who might otherwise seek care outside your practice.
Providers who offer teledermatology can expand their reach beyond their immediate geographic area.
Dermatology CPT codes BCBS covers, and the policy attached to each
A CPT code describes the specific dermatology procedure billed, and BCBS attaches coverage, prior authorization, and bundling rules to the code paired with its supporting diagnosis. The families below carry the most BCBS dermatology volume. Confirm the current policy and prior authorization status for each against the rendering affiliate’s medical policy, because edits and PA lists change.
| Service | CPT family | BCBS coverage note |
| Skin biopsy | 11102 to 11107 (tangential, punch, incisional, plus add-ons) | Covered with a supporting lesion diagnosis; watch add-on unit reporting |
| Destruction, premalignant lesions (actinic keratoses) | 17000 (first), 17003 (second to fourteenth), 17004 (fifteen or more) | Covered for AK (L57.0); unit count must match documented lesions |
| Destruction, benign lesions | 17110, 17111 | Requires documented symptoms (pain, bleeding, inflammation) or denied as cosmetic |
| Destruction, malignant lesions | 17260 to 17286 | Covered with malignant diagnosis and pathology support |
| Excision, benign | 11400 to 11446 (by site and size) | Size plus site drives the code; record excised diameter including margins |
| Excision, malignant | 11600 to 11646 (by site and size) | Pathology must support malignancy |
| Shave removal | 11300 to 11313 | Covered with medical indication |
| Mohs surgery | 17311 to 17315 | High-dollar; see the Mohs billing guide for staging and unit rules |
| Intralesional injection | 11900, 11901 | Covered for documented inflammatory or keloid indication |
| Office visit (E/M) | 99202 to 99205 (new), 99211 to 99215 (established) | See modifier 25 rules before billing an E/M with a same-day procedure |
| Dermatopathology | 88305 | Level IV surgical pathology for skin specimens |
Modifier 25 and the NCCI edits that bundle your dermatology claims
Modifier 25 reports a significant, separately identifiable evaluation and management service performed by the same provider on the same day as a procedure, and it is the single most scrutinized modifier in dermatology billing. BCBS auditors deny the E/M when the note does not show work beyond the usual pre and post service effort of the procedure itself. Append modifier 25 only when the documentation supports a distinct, separately reportable E/M, and make that distinction visible in the note.
National Correct Coding Initiative (NCCI) edits bundle code pairs that should not be reported together unless a modifier establishes that the services were distinct. In dermatology the recurring edits involve a biopsy reported with a destruction or excision at the same session, an E/M reported with a minor procedure, and multiple-lesion procedures reported as separate units. When an edit is denied incorrectly, the appeal must cite the NCCI edit table to show that no edit exists for the pair, or that a modifier (59 or the X{EPSU} set, 25, 24, or 57 as applicable) correctly unbundles it.
Prior authorization for dermatology biologics and specialty drugs
Prior authorization for dermatology biologics and specialty drugs is the approval BCBS requires before it will cover high-cost agents such as Dupixent, Cosentyx, Skyrizi, Tremfya, Rinvoq, Cibinqo, Adbry, and Opzelura. These denials are preventable, but only if the submission addresses three things the payer always checks: the benefit pathway, step therapy, and safety criteria.
Medical benefit versus pharmacy benefit: A dermatology biologic can be covered under the medical benefit (provider-administered, billed buy-and-bill with a J-code) or the pharmacy benefit (dispensed through a specialty pharmacy), and the pathway determines who authorizes it and how you bill it. Validate the benefit type during eligibility before you build the authorization, because submitting to the wrong pathway produces an automatic denial.
Step therapy: Most BCBS plans require documented trial and failure of preferred therapies before approving a specialty agent. Record each prior therapy with the drug name, dose, dates, duration, and the reason: it failed or was not tolerated.
Safety criteria and quantity limits Plans verify that the patient is not on a contraindicated agent and that the request is within quantity limits.
BCBS of Texas Requirements for Opzelura
BCBS of Texas has specific prior authorization requirements for Opzelura (ruxolitinib cream). For atopic dermatitis, the patient must document a 30-day trial and failure of a topical corticosteroid for mild cases, or a medium- to high-potency topical corticosteroid for moderate cases. They must also fail one topical calcineurin inhibitor or crisaborole.
For vitiligo, the patient must document a 30-day trial and failure of either a medium- or high-potency topical corticosteroid, pimecrolimus cream, or tacrolimus ointment.
BCBS of New Jersey Requirements for Opzelura
BCBS of New Jersey has similar requirements with additional nuance. For atopic dermatitis, the plan requires documented failure of topical corticosteroids and calcineurin inhibitors. For some plans, failure of PDE-4 inhibitors like crisaborole is also required.
Safety restrictions for both states require that the patient not be receiving any systemic JAK inhibitors, therapeutic biologics, or potent immunosuppressants. Quantity limits are also enforced, typically one 60g tube per week or 100g every two weeks.
BCBS of Western New York Guidelines for UV Therapy
BCBS of Western New York has detailed guidelines for ultraviolet light therapy. Excimer and pulsed dye lasers may be considered medically necessary for mild to moderate localized plaque psoriasis affecting 10% or less of the body surface area in individuals who have not adequately responded to 3 or more months of topical treatments. Treatment of vitiligo and localized atopic dermatitis/eczema may also be covered.
No more than thirteen treatments per course and three courses per year are considered medically necessary. The combined use of pulsed dye laser and ultraviolet B is considered experimental and investigational.
The BCBS dermatology appeals ladder, in the order that wins
The BCBS dermatology appeal process moves through defined levels, and the order in which you use them changes your overturn odds. Move in this sequence.
1. Peer-to-peer review
Where a clinical reviewer or a delegated vendor (Carelon or eviCore) issued the denial, request a peer-to-peer before you file a written appeal. The treating physician, not billing staff, makes this call, and it should match the plan’s clinical criteria point by point against the patient’s documented history. A peer-to-peer resolved in your favor avoids the written appeal entirely. [VERIFY peer-to-peer window; commonly within 72 hours of denial.]
2. Internal appeal
File the plan’s internal appeal within the affiliate’s window. Commercial Blue plans generally allow 60 to 180 days; Medicare Advantage allows 60 days. Attach the clinical note, the prior-therapy record, and a direct citation to the plan’s medical policy. [VERIFY windows per affiliate.]
3. External or independent review.
If the internal appeal fails, request external review through the state’s process. Timelines and guarantees vary by state.
Medicare Advantage note.
BCBS Medicare Advantage denials follow a federally mandated, multi-level CMS appeal chain rather than the commercial internal process. Under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), BCBS MA plans must issue prior-authorization denials with a specific clinical reason tied to the individual patient. A denial that lacks a patient-specific rationale is itself grounds to appeal.
Keep a payer-specific prior authorization and appeal matrix, updated at least quarterly, that records each affiliate’s filing window, appeal window, portal, and delegated reviewer.
Coordination of benefits and secondary dermatology claims
Coordination of benefits determines which payer pays first when a dermatology patient carries more than one plan, and COB errors are a common, preventable BCBS denial. A recurring 2026 pattern: BCBS denies secondary dermatology claims for timely filing because affiliates measure the window inconsistently, some from the date of service and some from the primary payer’s EOB date. Confirm the patient’s primary and secondary order at eligibility, file the secondary claim with the primary EOB attached, and confirm the affiliate’s secondary timely filing rule so a clean secondary claim is not lost to a window mismatch.
Who actually reviews your BCBS prior authorization
For many dermatology and specialty services, BCBS does not review the prior authorization itself; it delegates the decision to a third-party benefits manager. The two most common are Carelon Medical Benefits Management (formerly AIM Specialty Health) and eviCore. When the authorization is delegated, the denial is issued by that vendor, and the peer-to-peer request and appeal must route to the vendor, not to BCBS. Your denial letter names the issuing entity; read it before you act, because sending the appeal to the wrong reviewer wastes an appeal window. Confirm which dermatology service lines each affiliate delegates, since this varies by plan and changes.
What BCBS Auditors Look For
BCBS conducts targeted audits on dermatology codes. A concerning pattern has emerged where claims for lesion destruction have been denied for “medical necessity” even when documentation showed proper diagnoses. The problem is not the diagnosis but the specificity of the documentation.
For actinic keratosis and other pre-malignant lesions, ICD-10 guidelines state that code assignment is based on the provider’s diagnostic statement that the condition exists, not on clinical criteria used to establish the diagnosis. The documentation must clearly state the diagnosis.
For benign lesions, providers should document specific symptoms such as pain, bleeding, reddening or inflammation, or infection. Without specific documentation of symptoms, the payer may deny the claim as cosmetic.
Medical Necessity Letters
For specialty treatments like biologics or expensive topicals, a strong prior authorization submission should be included.
Include diagnosis with specific clinical criteria, failure of prior standard therapies with dates and durations, current disease severity and functional impact, involvement of a specialist prescriber, and, if applicable, BSA (Body Surface Area) measurements.
BCBS requires documentation of BSA for both atopic dermatitis (max 20%) and vitiligo (max 10%).
Without these objective measurements, the prior authorization submission is incomplete.
Provider Note Elements
For every dermatology encounter, your provider’s note should include patient demographics and insurance information.
Also include specific diagnosis with appropriate ICD-10 code, disease severity including BSA affected, complete treatment history with dates, durations, and outcomes, reasons for discontinuation of prior therapies, clinical rationale for the prescribed treatment, and confirmation of safety criteria (no contraindicated medications).
When appropriate, include objective measures such as validated severity scales (e.g., EASI for eczema, PASI for psoriasis, IGA for atopic dermatitis).
These objective measures strengthen prior authorization submissions and appeal letters.
Read the denial code first: BCBS dermatology CARC reference
A claim adjustment reason code (CARC) on the remittance tells you precisely why BCBS denied or adjusted the claim, and the code determines the correct response. Read it before you rework anything. The codes below cover the bulk of dermatology denials.
| CARC | Common dermatology cause | First action |
| CO-197 | No authorization, expired authorization, or service billed differs from what was authorized (different code, site, or units) | Check for retro-auth eligibility; if unavailable, appeal with documentation of scope or urgency |
| CO-96 | Service deemed not medically necessary | Appeal with the clinical note and the plan’s own medical policy citation; request peer-to-peer where a reviewer is involved |
| CO-29 | Claim received after the timely filing deadline | Appeal with proof of earlier submission (clearinghouse logs, EDI acknowledgments); confirm whether the affiliate measures from date of service or primary EOB date |
| CO-4 / CARC 4 | Procedure inconsistent with modifier, or a required modifier is missing (bundling) | Resubmit with the correct modifier (25, 59, X{EPSU}) and an NCCI edit-table citation |
| CO-16 | Claim lacks information needed for adjudication | Supply the missing data element and resubmit |
| CO-50 | Service not deemed a medical necessity by the payer’s policy | Treat as a medical-necessity appeal with documentation and policy citation |
| CO-45 | Charge exceeds the fee schedule or contracted amount | Contractual write-off, not an appeal, unless the contracted rate is misapplied |
Common Denial Reasons and How to Prevent Them
Missing Prior Authorization
Prior authorization is required for biologics, specialty medications, and certain surgical procedures. Submitting a claim without prior authorization is an automatic denial. No appeal can fix a missing authorization.
Verify prior authorization requirements for every patient and every service before scheduling. Submit prior authorization requests well ahead of planned treatment. Track authorization expiration dates.
Step Therapy Not Completed
Many BCBS plans require step therapy before approving expensive treatments. The Adbry denial case demonstrates that even if a patient has tried and failed one biologic, they may still need to try additional alternatives before the plan covers the requested medication.
Document all prior therapies with specific medication names, dates, durations, and outcomes. Include “failed” or “intolerant” language for each therapy that did not work. Provide clear rationale for why further alternatives would be ineffective or harmful.
Medical Necessity Not Established
For cosmetic services, BCBS auditors scrutinize the documentation for evidence of functional impairment. Without specific clinical findings, the claim will be denied.
Document specific symptoms (pain, bleeding, functional limitation). Include objective measures (BSA, severity scales).
Incomplete Documentation
A denial can occur simply because the documentation is incomplete. Missing BSA measurements, unclear diagnosis codes, or lack of prior therapy documentation are all preventable reasons for denial.
Use templates that prompt providers for all required documentation elements. Review claims before submission for completeness. Conduct internal audits to identify documentation gaps.
Cosmetic vs. Medical Classification
This is the most common and most preventable denial. If the documentation does not clearly establish that the service was medically necessary and not cosmetic, the claim will be denied.
Clearly document the functional impairment. Use specific diagnosis codes that reflect a medical condition, not a cosmetic concern.
Provide a treatment plan that addresses the medical condition, not simply the appearance.
How to Build a Denial-Proof Dermatology Practice?
Train Your Front Desk
Front desk staff should verify coverage before every appointment.
This includes checking referral requirements, prior authorization needs, and in-network status.
Build a Prior Authorization Workflow
Prior authorization is the single most common reason for dermatology claim denials. Build a systematic workflow around it.
- Identify services that require prior authorization.
- Submit requests 2-3 weeks before the scheduled treatment.
- Track approval status and follow up on pending requests.
- Maintain a log of authorization numbers and expiration dates.
- Set alerts for expiring authorizations.
Use Specialty-Specific Billing Support
Dermatology billing requires specialty-specific knowledge.
General billers may not understand the nuances of excision coding, modifier usage, or biologic prior authorization.
Consider investing in dermatology billing training for your team or outsourcing to a billing service with dermatology expertise.
The cost of training or outsourcing is often less than the revenue lost to preventable denials.
How UControl keeps BCBS dermatology claims paid
UControl Billing manages dermatology revenue cycles across all 50 states, which means the firm works every Blue affiliate’s policy set, portal, and appeal process, not just one. The team verifies benefit and funding type before the visit, codes to the supporting diagnosis with correct modifiers, builds biologic prior authorizations to each plan’s step-therapy and benefit-pathway rules, routes peer-to-peer requests and appeals to the correct reviewer, and works denials by CARC code rather than guesswork. The result is fewer first-pass denials and a faster, more predictable dermatology revenue cycle.
FAQs
Does BCBS cover dermatology?
Yes, when the service is medically necessary and documented to the plan’s policy. Cosmetic dermatology is excluded across nearly all Blue plans. Specific coverage, referral, and prior authorization rules are set by the patient’s local Blue affiliate.
Does BCBS require prior authorization for dermatology?
For routine office visits and most biopsies, usually no. For biologics, specialty drugs, certain surgical procedures, and phototherapy, usually yes. Verify at the procedure-code or drug level for the specific affiliate before the date of service.
Does BCBS cover teledermatology?
Many Blue plans cover teledermatology as a standard benefit. Confirm coverage and any visit cap for the patient’s plan.
Does BCBS cover cosmetic dermatology?
No. Procedures intended to change appearance within normal anatomic variation, such as chemical peels for wrinkles, laser hair removal, and microneedling for acne scars, are excluded. A procedure that is sometimes cosmetic and sometimes reconstructive is covered only when documentation establishes functional impairment.
Why was my BCBS dermatology claim denied?
Read the CARC code on the remittance. The most common dermatology denials are missing or mismatched authorization (CO-197), medical necessity (CO-96), timely filing (CO-29), and modifier or bundling errors (CO-4). Each has a different correct response. (See the denial code reference above.)
How long do I have to appeal a BCBS dermatology denial?
Commercial Blue plans generally allow 60 to 180 days; Medicare Advantage allows 60 days. Windows vary by affiliate, so confirm the specific plan’s deadline.
